642 episodios
- For patients with ROS1-positive lung cancer, treatment must contend not only with tumors in the lung but also the risk of it spreading to the brain and the eventual emergence of drug resistance. Nuvation Bio is addressing those challenges with Ibtrozi, an oral ROS1 inhibitor acquired through its purchase of AnHeart Therapeutics and developed to act in the central nervous system. David Hung, CEO of Nuvation Bio, discuses the company’s success in bringing the therapy to patients, its efforts to expand its use to earlier in the course of the disease, and how that first commercial product sets a foundation for a longer-term oncology business.
- Some cancer-driving proteins offer few ways for conventional drugs to target, leaving patients with limited options even when researchers understand what fuels their tumors. Remix Therapeutics is approaching that problem by developing oral small molecules that alter RNA processing to reduce production of those proteins. Pete Smith, co-founder and CEO of Remix, discusses the company’s experimental MYB-targeting therapy, the early evidence in adenoid cystic carcinoma, and whether changing how cells process RNA could open a new route to previously elusive cancer targets.
- Pain is one of medicine’s most common complaints, yet finding effective alternatives to opioids has proved remarkably difficult. Latigo Biotherapeutics is developing experimental medicines that target NaV1.8, a sodium channel involved in transmitting pain signals through peripheral nerves, with the goal of relieving pain without the addiction risk and other side effects associated with opioids. We spoke with Nima Farzan, CEO of Latigo, about the science behind the company’s approach to treating pain, what its clinical results suggest about the potential to reduce opioid use after surgery, and what clinicians and insurers will need to see beyond regulatory approval.
- Biotech investors have long considered scientific uncertainty, clinical setbacks, and commercial risk when making investments. John Stanford, founder and executive director of the policy advocacy organization Incubate argues that the life sciences venture capital firms he represents need to pay increasing attention to Washington due to instability at the U.S. Food and Drug Administration, competitive threats from China’s emergence as an innovation powerhouse, and reduced federal investment in research. Stanford discusses how drug-pricing policy and FDA leadership turnover influence which companies get funded, why he sees the Inflation Reduction Act’s treatment of small-molecule drugs as a particular problem, and why protecting American leadership requires supporting the entire drug-development ecosystem.
Developing an Off-the-Shelf Cell-Based Immunotherapy for Metastatic Breast Cancer
21/10/2026 | 41 minFor patients with metastatic breast cancer, successive treatments can lose effectiveness as tumors evolve and resistant cancer cells survive, leaving those who have received multiple therapies with limited options. BriaCell is seeking to address that problem with an experimental, off-the-shelf, cell-based immunotherapy designed to stimulate the immune system against multiple cancer-associated targets rather than a single target. Its lead candidate, Bria-IMT, is being studied in combination with a checkpoint inhibitor in a phase 3 trial, while its next-generation programs aim to offer personalized treatment using off-the-shelf cells. William Williams, CEO of BriaCell, discusses how its therapies work, what earlier clinical findings suggest, and the development path forward.
Más podcasts de Ciencias
Podcasts a la moda de Ciencias
Acerca de The Bio Report
The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.
Sitio web del podcastEscucha The Bio Report, The Rest Is Science y muchos más podcasts de todo el mundo con la aplicación de radio.net

Descarga la app gratuita: radio.net
- Añadir radios y podcasts a favoritos
- Transmisión por Wi-Fi y Bluetooth
- Carplay & Android Auto compatible
- Muchas otras funciones de la app
The Bio Report: Podcasts del grupo







































